Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0890B in R/R AML
NCT07617285Phase 1Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute myeloid leukemia (AML), sponsored by Peking University People's Hospital. Primary endpoints: Adverse Events at 12 months, Dose-limiting toxicity at 28 days and 1 more. Started May 2026; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07617285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617285.